NRXP
NRX Pharmaceuticals, Inc. Common Stock
Nasdaq · usd
NRX Pharmaceuticals, Inc. Common Stock (NRXP) trades at $2.15 (-15.70%) as of 7:58:20 PM EST on Nov 20, 2026, -10.42% over the past month. Market cap is $95.31M, with 4.6 days to cover in short interest.
Stock performance
How NRX Pharmaceuticals, Inc. Common Stock (NRXP) stock has performed from one day to one year, with its 52-week range.
- 1D
- -15.69%
- 1W
- -1.83%
- 1M
- -10.42%
- YTD
- -20.66%
- 1Y
- -4.02%
- 52-wk range
- $1.62 – $5.06
Key statistics
Today's trading snapshot for NRXP: day range, open, previous close, volume and market cap.
- Day range
- $2.14 – $2.53
- Open
- $2.53
- Prev close
- $2.55
- Volume
- 1.48M
- Market cap
- $95.31M
- Shares out
- 43.65M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for NRX Pharmaceuticals, Inc. Common Stock: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- 22.11
- P/B
- -47.99
- P/FCF
- —
- ROE
- 995.2%
- ROA
- -71.1%
- Debt/Equity
- -0.13
- Div yield
- 0.00%
As of Nov 20, 2026
8-K filings
Material corporate events NRX Pharmaceuticals, Inc. Common Stock has disclosed to the SEC on Form 8-K.
- Regulatory decisionNov 2, 2026
On October 30, 2026, NRx Pharmaceuticals, Inc. (the "Company") announced that the U.S. Food and Drug Administration (the "FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for Preservative-Free Ketamine, ahead of the November 10, 2026 goal date established under the Generic Drug User Fee Amendments ("GDUFA").
- Shareholder meeting noticeOct 16, 2026
On October 16, 2026, the board of directors (the "Board") of NRx Pharmaceuticals, Inc. (the "Company") established December 17, 2026 as the date of the 2026 Annual Meeting of Stockholders (the "2026 Annual Meeting") and set October 28, 2026 as the record date for determining stockholders entitled to vote at the 2026 Annual Meeting. The 2026 Annual Meeting will be held at 10:00 a.m., Eastern Time, in a virtual-only format conducted by live webcast.
- Regulatory decisionOct 5, 2026
The clinical trial has been approved by the U.S. Food and Drug Administration and is expected to begin enrolling patients.
- Regulatory decisionSep 16, 2026
On September 15, 2026, NRx Pharmaceuticals, Inc. (the "Company") issued a press release announcing that it has received a written communication from the Director of Regulatory Operations of the FDA Office of Generic Drugs advising the Company that the amendment to its Abbreviated New Drug Application (ANDA), previously classified as a Major Amendment, has been reclassified as a Minor Amendment.
- Investor presentationSep 14, 2026
On September 8, 2026, representatives of NRx Pharmaceuticals, Inc. (the "Company") used the investor presentation furnished as Exhibit 99.1 to this Current Report on Form 8-K in connection with presentations and meetings with investors and other persons. The Company may continue to use the investor presentation, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and other persons.
Dividend history and stock splits
NRX Pharmaceuticals, Inc. Common Stock's recent dividend payments and stock splits.
Dividends
No recent dividends.
Splits
- 1-for-10Apr 2, 2024
NRXP short interest
How heavily NRXP is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 4.6
- Short interest
- 10.46M
- Avg volume
- 2.29M
As of · reported to FINRA twice monthly.
NRXP news
The latest news and headlines about NRX Pharmaceuticals, Inc. Common Stock (NRXP).
- NRx Pharmaceuticals, Inc. (NRXP) Reports Q3 Loss, Misses Revenue EstimatesnegativeZacks Investment Research· Nov 16, 2026
- NRx Pharmaceuticals Begins Selling U.S.-Made, Preservative-Free Ketamine Amid Long-Running ShortagepositiveGlobeNewswire Inc.· Nov 11, 2026
- Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) Q2 Earnings Lag EstimatesneutralZacks Investment Research· Oct 29, 2026
- NRx Pharmaceuticals to Participate in Upcoming Investor ConferencespositiveGlobeNewswire Inc.· Sep 8, 2026
- NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common StockneutralBenzinga· Jun 3, 2026
Frequently asked questions
What is the NRX Pharmaceuticals, Inc. Common Stock (NRXP) stock price today?
NRX Pharmaceuticals, Inc. Common Stock (NRXP) is trading at $2.15 (-15.70% on the day) as of 7:58:20 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is NRX Pharmaceuticals, Inc. Common Stock?
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases.
What is the short interest in NRXP?
As of Oct 30, 2026, NRXP has 10.46M shares short and 4.6 days to cover.
What exchange is NRXP listed on?
NRX Pharmaceuticals, Inc. Common Stock (NRXP) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of NRXP with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a NRXP analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.